Navigation Links
Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity
Date:7/9/2009

BMI 27-35 kg/m2), combination treatment with pramlintide/metreleptin (360 mcg/5 mg twice daily) resulted in an average weight loss of 12.7% (25 pounds) from enrollment, significantly more than treatment with pramlintide alone (360 mcg twice daily) who experienced an average weight loss of 8.4% (17 pounds) or metreleptin alone (5 mg twice daily) who experienced an average weight loss of 8.2% (16 pounds).

Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information on Amylin Pharmaceuticals is available at http://www.amylin.com.

This press release contains forward-looking statements about Amylin, which involve risks and uncertainties. The Company's actual results could differ materially from those discussed due to a number of risks and uncertainties, including that our clinical trials may not start when planned and/or confirm previous results; our preclinical studies may not be predictive; our product candidates may not receive regulatory approval; and inherent scientific, regulatory and other risks in the drug development and commercialization process. These and additional risks and uncertainties are described more fully in the Company's most recently filed SEC documents, including its Form 10-Q. Amylin undertakes no duty to update these forward-looking statements.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Amylin Pharmaceuticals to Present at Piper Jaffray Europe Conference
2. Amylin Pharmaceuticals to Present at Goldman Sachs Annual Global Health Care Conference
3. Amylin Announces Preliminary Tabulation of Annual Meeting Results
4. Amylin Responds to Eastbourne Letter
5. Amylin Comments on RiskMetrics Report
6. Amylin Pharmaceuticals to Present at Deutsche Bank Health Care Conference
7. Amylin Co-Founder Announces Plans to Vote for Eastbourne Slate
8. Amylin Pharmaceuticals Announces a New Sales Approach to Better Target the Diabetes Market
9. Amylin Issues Statement in Response to Carl Icahn
10. Icahn Asks Amylin to Allow Discussions With Eastbourne
11. Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... Worcester, Mass. (PRWEB) , ... July 06, 2015 ... ... by Worcester Polytechnic Institute (WPI), offers new insights into how virulent fungi adapt ... block their spread, and how that battle leaves them temporarily weakened. These insights ...
(Date:7/6/2015)... Mass. (PRWEB) , ... July 06, 2015 , ... ... of simpler and cheaper molecular diagnostic tests are key drivers of the global ... growth of personalized medicine and the introduction of new companion diagnostic tests will ...
(Date:7/6/2015)... , July 6, 2015 ImmunoCellular Therapeutics, Ltd. ... an agreement with Novella Clinical (Novella), to ... patients with newly diagnosed glioblastoma. Novella is a full-service, ... to small to mid-sized oncology companies. The ICT-107 phase ... the US, Europe and ...
(Date:7/3/2015)... ... 2015 , ... The Alexander Group, a 30-year old, global ... typically known for its consummate professionalism-- embarks each year in a whacky marketing ... their day jobs. , "Our motto has always been work hard play hard," ...
Breaking Biology Technology:Worcester Polytechnic Institute Co-directs Study That Provides New Insights into the Genetics of Drug-Resistant Fungal Infections 2Worcester Polytechnic Institute Co-directs Study That Provides New Insights into the Genetics of Drug-Resistant Fungal Infections 3Worcester Polytechnic Institute Co-directs Study That Provides New Insights into the Genetics of Drug-Resistant Fungal Infections 4Demand for Personalized Medicine, Innovative Molecular Diagnostic Tests Spurring Big Growth, According to BCC Research 2Demand for Personalized Medicine, Innovative Molecular Diagnostic Tests Spurring Big Growth, According to BCC Research 3ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma 2The Alexander Group Declares Their Independence with a Bit of Levity 2
... INC. (Nasdaq: VION ) today announced that the ... 7.75% Convertible Senior Notes due,2012 (the "Notes"). The aggregate ... Company paid $2,260,416.67 in interest through the issuance of,shares ... in,2,539,200 shares of Common Stock, based on today,s closing ...
... Ltd. (NASDAQ: HCTL ), today announced unaudited results for ... Revenues for the first six months of 2007 were ... of 2006. The gross profit for the,first half of the ... in 2006. The net loss for such period was $(319) ...
... Advanced Life Sciences,Holdings, Inc. (Nasdaq: ADLS ), ... Listings Qualifications Department informed the Company that the,market ... million for 10,consecutive days, which is the requirement ... to Marketplace Rule 4450(b)(1)(A). Nasdaq,also informed the Company ...
Cached Biology Technology:Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes 2Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes 3Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results 2Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results 3Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter 2Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter 3Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter 4
(Date:6/24/2015)... 2015 This report provides market analysis of ... years. It contains an analysis of the drivers, challenges, ... impact from the short, medium, and long term perspective ... market, and technology trends that currently, prevail in the ... authorities to efficiently manage the increasing marine traffic and ...
(Date:6/24/2015)... , June 24, 2015 Biometry ... with emerging biometric password solution one face in. ... one face in, entering the ... ground-breaking and affordable multifactor-authentication biometric answer to the ... technology, provided in partnership with KeyLemon, one face ...
(Date:6/23/2015)... N.C. , June 23, 2015   ... today announced the results of a recent study ... accuracy on the wrist during activity. In a ... technology was compared along with the Apple Watch ... accurately measuring heart rate during activity. The study ...
Breaking Biology News(10 mins):Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3
... preserve grapes could help prevent allergies and boost healthy compounds ... Industry, the magazine of the SCI. The same technique could ... without the added sulphites that can cause asthma and other ... in storage for months and are usually treated with sulphur ...
... Researchers at Columbia University’s Mailman School of Public Health ... cancer. Using DNA isolated from serum samples as ... tumor suppressor genes that have been associated with the ... to prospectively examine potential biomarkers for early detection of ...
... normally used to treat insomnia, temporarily improved brain function ... in which the person is alert but cannot speak ... and eat without assistance after receiving the drug for ... the March 2007 issue of Annals of Neurology ( ...
Cached Biology News:Grape expectations for healthier wine 2Mailman School of Public Health researchers report blood DNA can be early predictor of liver cancer 2Insomnia drug can improve brain function 2
streptavidin, Alexa Fluor® 750–allophycocyanin conjugate (Alexa Fluor® 750–allophycocyanin streptavidin) *1 mg/mL*...
AedestaTM Animal Organ/Tissue Perfusion Soln....
Reusble. Uses in conjunction with the Apoptotic Cell Isolation Kit....
EGTA, 10 g. Ethylene glycol-O,O-bis-[2-amino-ethyl]-N,N,N,N,-tetraacetic acid.Assay: > 99.0%. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Biology Products: